RSS Feeds
Search

In-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

No results found for given criteria.
Please try to put more general criteria into your selection.

Related Reports

Market Research Reports provided by reports.iptechex.com
Brentuximab Vedotin – First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma)
May 2011 - 5 pages - $500
Hodgkin Lymphoma Therapy Area Pipeline Report
Nov 2010 - 143 pages - $1,495
Non-Hodgkin Lymphoma Therapy Area Pipeline Report
Nov 2010 - 622 pages - $1,495
Lymphoma - Pipeline Review, Q3 2011
Jul 2011 - 672 pages - $500
Lymphoma Therapy Area Pipeline Report
Nov 2010 - 233 pages - $1,495
Follicular Lymphoma - Pipeline Review, Q3 2011
Jul 2011 - 213 pages - $500
Non-Hodgkin's Lymphoma (NHL) - Drug Pipeline Analysis and Market Forecasts to 2015
Jan 2010 - 84 pages - $2,000
Hodgkin Lymphoma (HL) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Jun 2011 - 72 pages - $2,000
Mantle Cell Lymphoma - Pipeline Review, Q3 2011
Jul 2011 - 268 pages - $500
Cutaneous T-cell Lymphoma Therapy Area Pipeline Report
Nov 2010 - 101 pages - $1,495
More Related Market Research Reports >>>

Your selection

Industry sector
Animal health del
Diagnostic del
Therapeutic target
Oncology del
Lymphoma del
Hodgkin's lymphoma del
Development phase
Early Stage del

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us